Clinical implementation of a procedure to prepare bone marrow cells from cadaveric vertebral bodies

Bibliography

• 1  Fontes P, Rao AS, Carroll P et al. Bone marrow augmentation of donor–cell chimerism in kidney, liver, heart, and pancreas islet transplantation. Lancet344,151–155 (1994).
  Medline CASGoogle Scholar
• 2  Rao AS, Fontes P, Zeevi A et al. Combined bone marrow and whole organ transplantation from the same donor. Transplant. Proc.26,3377–3378 (1994).
  Medline CASGoogle Scholar
• 3  Pham SM, Keenan RJ, Rao AS et al. Perioperative donor bone marrow infusion augments chimerism in heart and lung transplant recipients. Ann. Thorac. Surg.60,1015–1020 (1995).
  Medline CASGoogle Scholar
• 4  Rao AS, Phil D, Fontes P et al. An attempt to induce tolerance with infusion of donor bone marrow in organ allograft recipients. Adv. Exp. Med. Biol.417,269–274 (1997).
  Medline CASGoogle Scholar
• 5  Millan MT, Shizuru JA, Hoffmann P et al. Mixed chimerism and immunosuppressive drug withdrawal after HLA-mismatched kidney and hematopoietic progenitor transplantation. Transplantation73,1386–1391 (2002).
  MedlineGoogle Scholar
• 6  Azari KK, Imbriglia JE, Goitz RJ et al. Technical aspects of the recipient operation in hand transplantation. J. Reconstr. Microsurg. doi: 10.1055/s-0031-1285820 (2011) (Epub ahead of print).
  MedlineGoogle Scholar
• 7  Gorantla VS, Schneeberger S, Moore LR et al. Development and validation of a procedure to isolate viable bone marrow cells from the vertebrae of cadaveric organ donors for composite organ grafting. Cytotherapy DOI: 10.3109/14653249.2011.605350 (2011) (Epub ahead of print).
  MedlineGoogle Scholar
• 8  Clinical and Laboratory Standards Institute.Laboratory Documents: Development and Control; Approved Guideline (Fifth Edition). Clinical and Laboratory Standards Institute, Wayne, PA, USA, 1–81 (2006).
  Google Scholar
• 9  Sutherland DR, Anderson L, Keeney M, Nayar R, Chin-Yee I. The ISHAGE guidelines for CD34⁺ cell determination by flow cytometry. International Society of Hematotherapy and Graft Engineering. J. Hematother.5,213–226 (1996).
  Medline CASGoogle Scholar
• 10  Donnenberg AD, Koch EK, Griffin DL et al. Viability of cryopreserved BM progenitor cells stored for more than a decade. Cytotherapy4,157–163 (2002).
  Medline CASGoogle Scholar
• 11  Mather JP, Roberts PE. Acridine orange–ethidium bromide viability determination. In: Introduction to Cell and Tissue Culture: Theory and Technique. Plenum Press, New York, NY, USA, 74 (1998).
  Google Scholar
• 12  Donnenberg AD. T-cell depletion and allograft engineering. In: Hematopoietic Stem Cell Therapy. Ball ED, Lister J, Law P (Eds). Churchill Livingstone, Philadelphia, PA, USA 335–344 (2000).
  Google Scholar
• 13  Sahota A, Gao S, Hayes J, Jindal RM. Microchimerism and rejection: a meta-analysis. Clin. Transplant.14,345–350 (2000).
  Medline CASGoogle Scholar
• 14  Sharp TG, Sachs DH, Matthews JG, Maples J, Woody JN, Rosenberg SA. Harvest of human bone marrow directly from bone. J. Immunol. Methods69,187–195 (1984).
  Medline CASGoogle Scholar
• 15  Rybka WB, Fontes PA, Rao AS et al. Hematopoietic progenitor cell content of vertebral body marrow used for combined solid organ and bone marrow transplantation. Transplantation59,871–874 (1995).
  Medline CASGoogle Scholar
• 16  Moore S. Pancreatic DNase. In: The Enzymes (Volume 14). Boyer PD (Ed.). Academic Press, NY, USA, 281–296 (1981).
  Google Scholar
• 17  Windrum P, Morris TCM, Drake MB, Niederwieser D, Ruutu T. Variation in dimethyl sulfoxide use in stem cell transplantation: a survey of EBMT centres. Bone Marrow Transplant.36,601–603 (2005).
  Medline CASGoogle Scholar